Gedeon Richter (RICHTER) Investor Update summary

Strategic Direction, Market Opportunity, and Industry Context

• Women's Healthcare is positioned as a core business with significant social impact and growth potential, as larger pharma companies deprioritize the field, creating a $1 trillion opportunity and a niche for innovation in areas like endometriosis and menopause.

• The business has evolved from a regional contraceptives producer to a pan-European and global player, targeting a full spectrum of women’s health conditions and aiming to be the No. 1 WHC player in Europe by 2030.

• Strategic acquisitions and partnerships have expanded the portfolio into benign gynecological conditions, fertility, and menopause treatments.

• Pharma pipelines are not fully aligned with the burden of disability in women's health, highlighting innovation gaps.

• The company is not dependent on any single product's success, providing financial stability and flexibility for future innovation.

Recent Acquisitions, R&D Expansion, and Portfolio Evolution

• Two major acquisitions—Mithra and BCI Pharma—enable full control over the E4 (estetrol) platform, including R&D, IP, and future indications, and add significant in-house research capabilities.

• Mithra’s E4 platform and related R&D assets were acquired for €175mn, securing global rights to DrovelisⓇ/EstelleⓇ and Donesta®.

• The BCI Pharma acquisition for €12mn brings a proprietary library of over 2,000 molecules and strengthens early-stage research in women's health.

• These moves provide control over key assets, future cash flows, and a foundation for innovative gynecological research.

• The pipeline is robust for the near term, but new R&D capabilities are needed to address potential gaps by the late 2020s.

Product Portfolio and Innovation

• Leading provider of oral contraceptives in Europe, with innovative products like DrovelisⓇ and EvraⓇ enhancing market position.

• Fertility portfolio includes Bemfola, Cyclogest®, and ExEm Foam, addressing a growing global infertility market.

• Ryeqo® addresses high unmet need in endometriosis, with rapid uptake and significant patient reach.

• Menopause treatments such as Lenzetto® and Vagirux® show strong growth, with Donesta® in late-stage development.

• Ambition to become Europe's leading provider in regular contraception by year-end, supported by both organic and inorganic growth.